Naglazyme (Galsulfase)
- Name: Naglazyme
- Generic Name: Galsulfase
- Dosage Form & Strength: 5 mg/5 mL (1 mg/mL) single-dose vial
- Manufactured: BioMarin Pharmaceutical Inc.
Naglazyme is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme.
Naglazyme uses:
Mucopolysaccharidosis VI (also known as MPS VI Maroteaux-Lamy syndrome). It is a rare metabolic disorder in which the body cannot produce certain sugar molecules called glycosaminoglycans.
Note: Naglazyme (Galsulfase) is an FDA-approved medicine.
- Healthcare professionals observed some reactions in patients during and up to 24 hours after the medicine infusion. Some of the reactions were life-threatening, with many worst symptoms. If anaphylaxis or other severe hypersensitivity reactions occur, discontinue medicine administration immediately, and give appropriate medical treatment to patients.
- Experts observed membranous glomerulonephritis with Type 3 while treatment with Naglazyme 1 mg, as with other enzyme replacement therapies. If immune-mediated reactions occur, discontinue the administration of Naglazyme, and initiate appropriate medical treatment.
- Exercise caution when administering Naglazyme to patients susceptible to fluid volume overloads, like patients with 20 kg or less weight, patients with acute underlying respiratory illness, or patients with compromised cardiac and respiratory function, as congestive heart failure can occur. Make appropriate medical support and monitoring measures readily available during drug infusion. Some patients may require longer observation times that should be based on the Patient’s individual needs.
- It is seen that Sleep apnea is common in MPS VI patients, and earlier treatment with an antihistamine can increase the risk of apneic episodes. Patients who use supplemental oxygen or continuous positive airway pressure during sleep should have these treatments quickly available during infusion in the event of an infusion reaction.
- Due to the potential for infusion reactions, patients should receive antihistamines with or without antipyretics before infusion. Despite routine earlier treatment with antihistamines, infusion reactions, some severe, occurred in 33 of 59 (56%) patients treated with Naglazyme. If severe infusion reactions occur, discontinue the infusion immediately, Naglazyme and start appropriate treatment.
- Spinal or cervical cord compression (SCC) and resultant myelopathy are serious complications of MPS VI. According to professionals, SCC is expected to occur in the natural history of the disease, including in patients treated with Naglazyme.
What documents are required to import Naglazyme to India?
Naglazyme (Galsulfase) can be imported only by patients or government hospitals on the patients’ names.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by the government of India)
How does the order be confirmed?
The order will be confirmed only after the receipt of the following:
- A valid prescription from Doctor
- Import permit, if applicable
Is Naglazyme Biomarin available in India?
Naglazyme is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
- IPN (Indian Pharma Network) helps import cancer and rare medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from Canada, Europe, the USA and Australia
- Ensuring 100% transparency.
NAGLAZYME can be made available in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune and other cities in India.
Indian Pharma Network can facilitate the supply of Naglazyme (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact or mail @ – info@indianpharmanetwork.in +91 9310090915- Toll-Free – 1800-889-1064 for Naglazyme price in India.
We guarantee quality and delivery worldwide per the buyer’s requirements.
Indian Pharma Network can source the Naglazyme Injection (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the mechanism of action of Naglazyme?
Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. Naglazyme is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. The drug Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of Galsulfase to specific mannose-6-phosphate receptors.
What is the route of administration for Naglazyme?
Naglazyme infusion is intravenously. The recommended dosage regimen of NAGLAZYME is 1 mg per kg of body weight, administered once weekly.
What does Naglazyme treat?
Naglazyme (Galsulfase) treats patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome).
What is the price of Naglazyme in India?
To know the Naglazyme price in India, you can call or WhatsApp +91-9310090915 or email info@indianpharmanetwork.in.
What is the dosage and form of Naglazyme available?
Naglazyme is available for Injection: 100 mg lyophilized powder in a single-dose vial.
What are the Highlights of prescribing information for Naglazyme?
Click Here to download full Naglazyme prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.